



1617  
1Fu

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
<u>June 28, 2005</u> Date	 Shelley P.M. Fussey

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Philip E. Thorpe Sophia Ran and  
Rolf A. Brekken (As Amended)

Group Art Unit: 1617

Serial No.: 09/351,149

Examiner: Sharareh, S.

Filed: July 12, 1999

Atty. Dkt. No.: 3999.002383

For: CANCER TREATMENT KITS COMPRISING  
THERAPEUTIC CONJUGATES THAT BIND  
TO AMINOPHOSPHOLIPIDS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22131-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. According to 37 C.F.R. § 1.98(a)(2)(ii), copies of listed U.S. patents are no longer required.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information. In the alternative, for completeness and to most fully comply with the duty of disclosure, the enclosed document should be placed in the file in accordance with 37 C.F.R. § 1.97(i).

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed in the accompanying Form PTO-1449 was not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed document was cited in an Official Action on the merits in a co-pending application of one of the present inventors, U.S. Application Serial No. 09/998,833 (Attorney Docket No. 4001.002299), mailed from the P.T.O. on March 28, 2005, and could not have been submitted before receipt. The present statement is being filed within three months of the date of the referenced Official Action, and is thus timely.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002383.


Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.  
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

5353 W. Alabama, Suite 306  
Houston, Texas, 77056  
(832) 886-5834  
Date: June 28, 2005



Form PTO-1449 (modified)

Temp. Atty. Docket No.  
3999.002383Serial No.  
09/351,149

List of Patents and Publications for Applicant's

Applicant  
Thorpe *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 12, 1999Group:  
1617U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A43	5,725,856	March 10, 1998	Hudziak, et al.	424	130.1	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)